N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial

S. Marlene Grenon, Christopher D. Owens, Hugh Alley, Karen Chong, Priscilla K. Yen, William Harris, Millie Hughes-Fulford, Michael S. Conte

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270

Original languageEnglish (US)
Pages (from-to)263-274
Number of pages12
JournalVascular Medicine (United Kingdom)
Issue number5
StatePublished - Oct 2013
Externally publishedYes


  • fatty acids
  • peripheral artery disease
  • randomized controlled trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: The OMEGA-PAD trial'. Together they form a unique fingerprint.

Cite this